je.st
news
Merck Announces Third-Quarter 2013 Financial Results
2013-10-28 12:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38 Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange Strong Growth in Vaccines and Immunology as well as ISENTRESS Breakthrough Therapy Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Mercks Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2013. $ in millions, except EPS amounts ThirdQuarter2013 ThirdQuarter2012 Language: English Contact: MerckMedia Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||